Valuation: Pelthos Therapeutics Inc.

Market Cap 77.91M 69.2M 64.71M 58.97M 111M 7.5B 113M 783M 303M 3.82B 293M 286M 12.27B P/E 2026 *
-1.19x
P/E 2027 * -7.23x
Enterprise Value 77.91M 69.2M 64.71M 58.97M 111M 7.5B 113M 783M 303M 3.82B 293M 286M 12.27B EV / Sales 2026 *
1.22x
EV / Sales 2027 * 0.69x
Free-Float
49.9%
Yield 2026 *
-
Yield 2027 * -
1 day-3.14%
1 week-9.15%
Current month-3.14%
1 month-18.01%
3 months-27.32%
6 months-4.46%
Current year-34.35%
1 week 20.16
Extreme 20.165
22.9
1 month 18.2
Extreme 18.205
25.6
Current year 18.19
Extreme 18.19
30.99
1 year 18.19
Extreme 18.19
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap. Importance
02/07/26 Sell

Director

-558 0.0161%
02/07/26 Sell

Director

-786 0.0226%
02/07/26 Sell

Chairman

-797 0.0229%
Change 5-day change 1-year change 3-year change Capi.($)
-3.14%-9.15%-24.63% - 80.44M
-0.62%-2.71%+39.30%+114.07% 1,031B
-2.30%-4.44%+39.03%+66.07% 638B
-0.63%-1.96%+6.36%+74.38% 462B
-1.03%-2.82%+59.56%+39.69% 359B
-0.03%-3.96%+23.63%+39.35% 335B
-1.58%-0.76%+13.50%+25.77% 273B
-2.02%-2.97%-3.25%+8.38% 253B
-3.38%+0.30%+36.44%+51.54% 228B
-1.04%-1.46%+32.70%+96.82% 185B
Average -1.58%-2.49%+22.26%+57.34% 376.39B
Weighted average by Cap. -1.25%-1.89%+30.51%+69.18%

Financials

2026 *2027 *
Net sales 63.75M 56.62M 52.95M 48.25M 90.84M 6.14B 92.09M 641M 248M 3.13B 239M 234M 10.04B 112M 99.67M 93.21M 84.94M 160M 10.8B 162M 1.13B 437M 5.5B 421M 412M 17.67B
Net income -62.08M -55.14M -51.57M -46.99M -88.47M -5.98B -89.68M -624M -241M -3.04B -233M -228M -9.78B -24.96M -22.17M -20.73M -18.89M -35.56M -2.4B -36.05M -251M -97.08M -1.22B -93.7M -91.67M -3.93B
Net Debt - -
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
01/10/26 US$20.35 -3.14% 44,590
30/09/26 US$21.01 +0.43% 5,453
29/09/26 US$20.92 -1.55% 9,445
28/09/26 US$21.25 -4.24% 12,007
25/09/26 US$22.19 -0.94% 14,850
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
20.35USD
Average target price
53.14USD
Spread / Average Target
+161.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTHS Stock